Analysts Offer Predictions for MSLE FY2030 Earnings

Satellos Bioscience Inc. (NASDAQ:MSLE) – Analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Satellos Bioscience in a research report issued on Monday, March 30th. HC Wainwright analyst A. He forecasts that the company will earn $0.34 per share for the year. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock.

Satellos Bioscience (NASDAQ:MSLE) last posted its quarterly earnings results on Friday, March 27th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.11).

Several other equities analysts have also commented on MSLE. Wall Street Zen lowered shares of Satellos Bioscience to a “strong sell” rating in a research report on Saturday, March 14th. Zacks Research upgraded shares of Satellos Bioscience to a “hold” rating in a report on Tuesday, February 10th. Cantor Fitzgerald began coverage on shares of Satellos Bioscience in a research note on Wednesday, March 11th. They set an “overweight” rating for the company. Finally, Weiss Ratings initiated coverage on Satellos Bioscience in a report on Wednesday, February 11th. They set a “sell (d-)” rating for the company. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $11.00.

Satellos Bioscience Stock Performance

Shares of MSLE stock opened at $6.04 on Tuesday. Satellos Bioscience has a 1-year low of $4.53 and a 1-year high of $13.39. The stock has a market cap of $93.38 million, a PE ratio of -3.90 and a beta of 1.37.

Key Satellos Bioscience News

Here are the key news stories impacting Satellos Bioscience this week:

• Positive Sentiment: HC Wainwright raised several near‑term EPS estimates (Q2 & Q3 2026, Q4 2026, Q2 & Q3 2027) and boosted FY2026/FY2027 outlooks, reflecting smaller expected losses in the nearer quarters — a potential positive catalyst for sentiment and valuation.
• Positive Sentiment: The analyst maintained a “Buy” rating and an $11.00 price target, signaling continued analyst conviction in upside from current levels and supporting investor interest.
• Neutral Sentiment: HC Wainwright published a long‑range FY2030 estimate (EPS $0.34) that implies a substantial turnaround, but this is distant and speculative; treat as a long‑term scenario rather than near‑term proof. Article Title
• Negative Sentiment: There are also downward revisions: Q1 2027 was cut (to a larger expected loss) and HC Wainwright trimmed FY2028 and FY2029 EPS (wider losses than previously modeled). These longer‑dated negative revisions increase uncertainty around the sustainability of the recovery.
• Negative Sentiment: Satellos reported an EPS miss in its most recent quarter (reported loss larger than consensus), a likely driver of some of the model adjustments and a reminder of execution risk going forward.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.